Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This Phase 2 study evaluates the efficacy and safety of MRTX849 monotherapy and in
combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C
mutation and any PD-L1 TPS and who are candidates for first-line treatment.